|
US4882335A
(en)
*
|
1988-06-13 |
1989-11-21 |
Alko Limited |
Method for treating alcohol-drinking response
|
|
US6271239B1
(en)
*
|
1992-04-13 |
2001-08-07 |
Regents Of The University Of Minnesota |
Delta opioid receptor-selective benzylidene-substituted morphinans
|
|
US5352680A
(en)
*
|
1992-07-15 |
1994-10-04 |
Regents Of The University Of Minnesota |
Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
|
|
US6096756A
(en)
*
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
|
US5580876A
(en)
*
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
|
USRE36547E
(en)
*
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
|
US5298622A
(en)
*
|
1993-05-12 |
1994-03-29 |
Regents Of The University Of Minnesota |
Spiroindane opiate analogs
|
|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
|
US5587381A
(en)
*
|
1995-03-27 |
1996-12-24 |
Sinclair; John D. |
Method for terminating methadone maintenance through extinction of the opiate-taking responses
|
|
WO1997018781A1
(en)
*
|
1995-11-20 |
1997-05-29 |
University Of Miami |
Method of treating nicotine dependence
|
|
US5878750A
(en)
*
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US5780479A
(en)
*
|
1997-04-04 |
1998-07-14 |
Regents Of The University Of Minnesota |
Use of opioid antagonists to treat impulse-control disorders
|
|
BR9813826A
(pt)
|
1997-12-22 |
2000-10-10 |
Euro Celtique Sa |
Potencial de uso abusivo de administração oral de opióide analgésico
|
|
SI2266564T1
(sl)
|
1997-12-22 |
2013-07-31 |
Euro-Celtique S.A. |
Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
AU1807401A
(en)
*
|
1999-11-30 |
2001-06-12 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
|
SI1299104T1
(sl)
|
2000-02-08 |
2009-10-31 |
Euro Celtique Sa |
Oralne formulacije opioidnih agonistov, varne pred zlorabo
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
|
US6262062B1
(en)
*
|
2000-08-15 |
2001-07-17 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US6846831B2
(en)
|
2000-08-15 |
2005-01-25 |
Cpd, Llc |
Method of treating the syndrome of lipodystrophy
|
|
US6528520B2
(en)
*
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
EP1387673B1
(en)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
|
EP1411352B1
(en)
*
|
2001-07-13 |
2012-01-11 |
ARKRAY, Inc. |
Analysing instrument and lancet-integrated attachment for concentration measuring device
|
|
SI1416842T1
(sl)
*
|
2001-07-18 |
2009-06-30 |
Euro Celtique Sa |
Farmacevtske kombinacije oksikodona in naloksona
|
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
DK1414451T3
(da)
|
2001-08-06 |
2009-08-10 |
Euro Celtique Sa |
Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
|
|
US20030153590A1
(en)
*
|
2001-08-14 |
2003-08-14 |
Oy Contral Pharma Ltd |
Method of treating alcoholism or alcohol abuse
|
|
DE20308437U1
(de)
|
2002-04-05 |
2003-11-13 |
Euro Celtique Sa |
Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
|
|
US7923454B2
(en)
*
|
2002-05-17 |
2011-04-12 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
US7501433B2
(en)
*
|
2002-05-17 |
2009-03-10 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
PT2561860T
(pt)
*
|
2002-05-31 |
2018-05-08 |
Titan Pharmaceuticals Inc |
Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
|
|
AU2003270778B2
(en)
*
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
|
ZA200507877B
(en)
|
2003-03-31 |
2007-01-31 |
Titan Pharmaceuticals Inc |
Implantable polymeric device for sustained release of dopamine agonist
|
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
AU2004229551A1
(en)
*
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US8017622B2
(en)
*
|
2003-05-16 |
2011-09-13 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
US20060009478A1
(en)
*
|
2003-10-15 |
2006-01-12 |
Nadav Friedmann |
Methods for the treatment of back pain
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
HUE032156T2
(en)
|
2006-06-19 |
2017-09-28 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical preparations
|
|
WO2008051902A2
(en)
*
|
2006-10-20 |
2008-05-02 |
Cpd, Llc |
Method of restoring the incretin effect
|
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
|
SI2307420T1
(sl)
*
|
2008-04-24 |
2012-05-31 |
Janssen Pharmaceutica Nv |
Predzdravila nalmefen di estra
|
|
EP2291380B1
(en)
*
|
2008-04-24 |
2011-09-07 |
Janssen Pharmaceutica N.V. |
Nalmefene prodrugs
|
|
SI2317991T1
(sl)
*
|
2008-07-07 |
2017-09-29 |
Euro-Celtique S.A. |
Uporaba opioidnih antagonistov za zdravljenje retencije urina
|
|
CA2754853C
(en)
|
2009-03-10 |
2015-04-28 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
|
US20140005216A1
(en)
|
2012-06-27 |
2014-01-02 |
H. Lundbeck A/S |
Nalmefene for reduction of alcohol consumption in specific target populations
|
|
JP6419780B2
(ja)
*
|
2013-04-17 |
2018-11-07 |
ハー・ルンドベック・アクチエゼルスカベット |
睡眠障害患者の治療のためのナルメフェン
|
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
|
WO2015163486A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Otsuka Pharmaceutical Co., Ltd. |
Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
|
|
CN107405343A
(zh)
|
2014-11-07 |
2017-11-28 |
明尼苏达大学董事会 |
可用于治疗疾病的盐和组合物
|
|
WO2017184819A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Taiwanj Pharmaceuticals Co., Ltd. |
Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
|